# Castle Biosciences Inc. (CSTL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $35.14, market value $1.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Castle Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.0×**. Each dollar of revenue is priced at 3.0×.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -0.0%** (5-yr avg -1.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -9.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -7.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -5.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -7.0%**. Return on all capital, debt included, is -7.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -3.4%**. Each dollar of assets produces -3.4% of profit.

## Growth
- **Revenue growth (1 yr): 3.7%** (3-yr 35.9%/yr, 5-yr 40.6%/yr). Revenue grew 3.7% over the last year, against 40.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -233.9%**. Earnings per share fell 233.9%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 6.5×**. It would take 6.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 5.26** (quick 5.26). Current assets cover the next year's liabilities 5.26 times.
- **Altman Z-score: 8.08**. A Z-score of 8.08 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Castle Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Castle Biosciences Inc.; the consensus is strong_buy, with an average price target of $46.70 (+33% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 37.0%** (YTD -10.2%, 3-mo 15.0%). The shares are up 37.0% over twelve months including dividends.
- **From 52-week high: -20.6%** (98.3% above the low). Trading 21% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.96** (volatility 58%). Beta of 0.96 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CSTL · Page: https://foliofundamentals.com/stocks/cstl

Not investment advice.